Last week the drug development company focused on rare diseases reported its results for the year ended December 2015. Revenues of C$4m exceeded our C$2.5m expectation. This was due to a higher amount of revenues recognised under the service agreement with the company’s partner on KIACTATM Auven Therapeutics and VIMINDTM license agreement with FB Health. However it should be noted that the cash element of these revenues totaled C$1.3m. On that same basis the company also beat our projec
04 Mar 2016
FY2015 results reveal small profit but focus now on vital Q2 KIACTATM data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY2015 results reveal small profit but focus now on vital Q2 KIACTATM data
Blue Star Capital Plc (BLU:LON) | 0.0 0 0.0% | Mkt Cap: 1.53m
- Published:
04 Mar 2016 -
Author:
Derren Nathan -
Pages:
6
Last week the drug development company focused on rare diseases reported its results for the year ended December 2015. Revenues of C$4m exceeded our C$2.5m expectation. This was due to a higher amount of revenues recognised under the service agreement with the company’s partner on KIACTATM Auven Therapeutics and VIMINDTM license agreement with FB Health. However it should be noted that the cash element of these revenues totaled C$1.3m. On that same basis the company also beat our projec